Taisho Pharmaceutical Co., Ltd.

Nec Corporation

Nissan Chemical Industries Limited

Yoshinori Sekiguchi

Katsuo Hatayama

Toshihito Kumagai

Shoichi Kuroda

Yusuke Oka

Yuri Amada

Tsuyoshi Shibata

Toshio Nakamura

Atsuro Nakazato

Masato Hayashi

Taketoshi Okubo

Naoya Ono

Yutaka Kawashima

Takahiro Oi

Tetsuya Yabuuchi

Tetsuo Takayama

Takeshi Kuwada

Takeshi Koami

Hiroshi Ohta

Takaaki Ishii

Thuy-Anh Tran

Shuji Yamamoto

Nigel Robert Arnold Beeley

Hajime Asanuma

Dai Nozawa

Fumihito Ushiyama

Takanori Shimizu

Munekazu Aoki

Bryan Aubrey Kramer

Madoka Kawamura

Fumito Uneuchi

Hisaya Wada

Xiang-Min Sun

Kumi Abe

Yoshihisa Shirasaki

Daisuke Wakasugi

Kosuke Kanuma

Koumei Ohta

Shigetada Sasako

Tomoko Ishizaka

Takayuki Nagatsuka

Rie Nishikawa

Yoshihiro Migita

Taro Matsumoto

Katsunori Omodera

Yuri Fujisawa

Provided are novel compounds that bind to FKBP12 or pharmaceutically acceptable salts thereof, as well as new therapeutics useful in the prevention or treatment of alopecia which comprise those compounds or pharmaceutically acceptable salts thereof. Specifically, compounds represented by formula (1) [where Rrepresents either the following formula (2) or (3)] or pharmaceutically acceptable salts thereof are provided.

Azole derivative

A compound represented by formula (1) or a pharmaceutically acceptable salt thereof, which has a PI3 kinase &#x3b3; inhibitory effect and is useful as a prophylactic or therapeutic agent for articular rheumatism, Crohn's disease, irritable colitis, Sjoegren's syndrome, multiple sclerosis, systemic lupus erythematosus, asthma, atopic dermatitis, arteriosclerosis, organ transplant rejection, cancer, retinopathy, psoriasis, arthrosis deformans, age-related macular degeneration, type II diabetes, insulin resistance, obesity, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), hyperlipemia, etc.

Aminothiazole derivative

A compound represented by formula (I) or a pharmaceutically acceptable salt thereof has an effect of inhibiting CRTH2 and, therefore, is useful as a preventive or a remedy for allergic diseases such as asthma, atopic dermatitis and allergic rhinitis.

Isoquinoline derivative

Disclosed is an aminopyrrolidine compound represented by the formula [I] or a pharmaceutically acceptable salt thereof. The compound or the salt is useful as a prophylactic/therapeutic agent for mode disorder such as depression, anxiety disorder, anorexia, cachexia, pain and drug dependence, whose action relies on the MCreceptor antagonistic effect.

Aminopyrrolidine compound

It is intended to provide a drug which is efficacious against pathological conditions relating to arginine-vasopressin V1b receptor. More particularly speaking, it is intended to provide a drug which has a therapeutic or preventive effect on depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorders, hypertension, digestive diseases, drug addiction, epilepsy, brain infarction, brain ischemia, brain edema, head injury, inflammation, immune diseases, alopecia and so on. As the results of intensive studies, a novel 1,3-dihydro-2H-indol-2-one compound and a pyrrolidin-2-one compound fused with a heteroaromatic ring, which are highly selective antagonists of arginine-vasopressin V1b receptor, have high metabolic stabilities and show favorable brain penetration and high plasma concentrations, are found, thereby achieving the above objective.

1,3-dihydro-2H-indole-2-one compound and pyrrolidine-2-one compound fused with aromatic heterocycle

An object of the present invention is to provide a cyclic amine compound which has a potent inhibitory effect on the binding of &#x3b1;2C-adrenoceptor and is useful in preventing and treating disorders attributable to &#x3b1;2C-adrenoceptor. The above-described object is solved by the following cyclic amine compound, etc., 

Cyclic amine compound

The present invention relates to novel compounds of the formula (I) which act as MCH receptor antagonists. These compositions are useful in pharmaceutical compositions whose use includes prophylaxis or treatment of obesity, obesity related disorders, anxiety, or depression.

MCH receptor antagonists

A 1,3-dihydro-2H-indol-2-one derivative expressed by Formula 1 (wherein Ris a halogen atom, a Cto Calkyl group, etc., and Ris a hydrogen atom, a halogen atom, etc., or Ris in the 6-position of the indol-2-one and Rand Rjoin together to form a Cto Calkylene group, Ris a halogen atom, a hydroxyl group, etc., and Ris a hydrogen atom, a halogen atom, a Cto Calkyl group, etc., or Ris in the 3-position of the phenyl and Rand Rjoin together to form a methylenedioxy group, Ris a hydrogen atom or a fluorine atom, Ris an ethylamino group, a dimethylamino group, etc., Ris a Cto Calkoxy group, and Ris a Cto Calkoxy group), or a pharmaceutically acceptable salt of this derivative. This is a novel compound that has antagonistic activity against an aruginine-vasopressin V1receptor.

1,3-dihydro-2H-indol-2-one derivative

A chip type electronic part of the present invention includes tapered notches rising from the bottom of the body of a molding. With this configuration, the electronic part achieves a high volume efficiency and a great bonding strength to a circuit board after soldering.

Chip type electronic part

Indolo[2,3-b]quinoxaline derivatives

A solid electrolytic chip capacitor in which L-shaped portions of the anode terminal and cathode terminal form slanting surfaces which project beyond the projecting side surfaces of the resin sheathing.

Electrolytic chip capacitor

Aminoalkylthiazole derivative

Alkoxyphenylalkylamine derivatives

Growing community of inventors

Tokyo, Japan

Yoshinori Sekiguchi